Skip to main content
PMC home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 1999 Jun;76(2):164–175. doi: 10.1007/BF02344673

Does social medicine still matter in an era of molecular medicine?

Leon Eisenberg 1
PMCID: PMC3455991  PMID: 10924027

Abstract

To ask whether social medicine still matters may seem to be in poor taste at a symposium to honor Martin Cherkasky, but social medicine has always had the courage to take on difficult questions. There is all the more reason to do so when its legitimacy is challenged. The extraordinary findings emerging from the human genome project will revolutionize diagnostic and therapeutic methods in medicine. The power of medical interventions, for good and for harm, will increase enormously. However, in the next millennium, as in this one, social factors will continue to be decisive for health status. The distribution of health and disease in human populations reflects where people live, what they eat, the work they do, the air and the water they consume, their activity, their interconnectedness with others, and the status they occupy in the social order. Virchow's aphorism is as true today as it was in 1848: “If disease is an expression of individual life under unfavorable conditions, then epidemics must be indicative of mass disturbances of mass life”. Increasing longevity resulting from major economic transformations has made ours the age of chronic disease. Changes in diet and behavior transform genes that once conferred selective biologic advantage into health hazards. Although disease risk varies with social status, medical care makes an important difference for health outcomes. Access to care and the quality of care received are functions of social organization, the way care is financed, and political beliefs about the “deserving” and the “undeserving” poor. It is a moral indictment of the US that ours is the only industrialized society without universal health care coverage. In educating the American public about the social determinants of health, a goal Martin Cherkasky championed, the very power of the new molecular biology will help make our case. Social medicine is alive and well.

Full Text

The Full Text of this article is available as a PDF (683.6 KB).

References

  • 1.Eisenberg L. What makes persons patients and patients well? Am J Med. 1980;69:277–286. doi: 10.1016/0002-9343(80)90389-7. [DOI] [PubMed] [Google Scholar]
  • 2.Haldane JBS. Natural selection in man. Acta Genet Stat Med. 1956/1957;6:321–332. doi: 10.1159/000150849. [DOI] [PubMed] [Google Scholar]
  • 3.Black FL. Infectious diseases in primitive societies. Science. 1975;187:515–518. doi: 10.1126/science.163483. [DOI] [PubMed] [Google Scholar]
  • 4.Black FL. Why did they die? Science. 1992;258:1739–1740. doi: 10.1126/science.1465610. [DOI] [PubMed] [Google Scholar]
  • 5.Eisenberg L. Rudolf Ludwig Karl Virchow: where are you now that we need you? Am J Med. 1984;77:524–532. doi: 10.1016/0002-9343(84)90114-1. [DOI] [PubMed] [Google Scholar]
  • 6.Virchow R, Rosen G. What is social medicine? A genetic analysis of the concept. Bull Hist Med. 1947;21:674–733. [PubMed] [Google Scholar]
  • 7.Raoult D, Ndihokubwayo JP, Tissot-Dupont H, et al. Outbreak of epidemic typhus associated with trench fever in Burundi. Lancet. 1998;352:353–358. doi: 10.1016/S0140-6736(97)12433-3. [DOI] [PubMed] [Google Scholar]
  • 8.Kass EH. Infectious diseases and social change. J Infect Dis. 1971;123:110–114. doi: 10.1093/infdis/123.1.110. [DOI] [PubMed] [Google Scholar]
  • 9.McKeown T. The Role of Medicine: Dream, Mirage or Nemesis? London: Nuffield Hospital Trust; 1976. [Google Scholar]
  • 10.Himsworth HP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet. 1936;1:117–117. doi: 10.1093/ije/dyt203. [DOI] [PubMed] [Google Scholar]
  • 11.Hattersley AT. Genes versus environment in insulin-dependent diabetes: the phoney war. Lancet. 1997;349:147–148. doi: 10.1016/S0140-6736(05)60972-5. [DOI] [PubMed] [Google Scholar]
  • 12.Mutoni SA, Fonte MT, Stoduto S, et al. Incidence of insulin-dependent diabetes mellitus among Sardinian-heritage children born in Lazio region, Italy. Lancet. 1997;349:160–162. doi: 10.1016/s0140-6736(96)04241-9. [DOI] [PubMed] [Google Scholar]
  • 13.Cavalli Sforza LL, Piazza A. Human genomic diversity in Europe: a summary of recent research and prospects for the future. Eur J Hum Genet. 1993;1:3–18. doi: 10.1159/000472383. [DOI] [PubMed] [Google Scholar]
  • 14.Krolewski AS, Warram JH. Epidemiology of late complications of diabetes. In: Kahn CR, Weir GC, editors. Joslin's Diabetes Mellitus. 13th ed. Philadelphia: Lea and Febiger; 1999. pp. 605–619. [Google Scholar]
  • 15.Salmeron J, Manson JE, Stampfer M, et al. Dietary fibre, glycemic load and risk of NIDDM. JAMA. 1997;277:472–477. doi: 10.1001/jama.277.6.472. [DOI] [PubMed] [Google Scholar]
  • 16.Zimmet PZ. Kelley West lecture. Challenges in diabetes epidemiology—from West to the rest. Diabetes Care. 1991;15:232–252. doi: 10.2337/diacare.15.2.232. [DOI] [PubMed] [Google Scholar]
  • 17.Neel JV. Diabetes mellitus: a thrifty genotype rendered detrimental by “progress”? Am J Hum Genet. 1962;14:353–362. [PMC free article] [PubMed] [Google Scholar]
  • 18.Dowse GK, Zimmet PZ, Finch CF, Collins V. Decline in incidence of epidemic glucose intolerance in Nauruans: implications for the “thrifty genotype”. Am J Epidemiol. 1991;133:1093–1104. doi: 10.1093/oxfordjournals.aje.a115822. [DOI] [PubMed] [Google Scholar]
  • 19.Feudtner C. The want of control: ideas, innovations, and ideals in the modern management of diabetes mellitus. Bull Hist Med. 1995;69(1):66–90. [PubMed] [Google Scholar]
  • 20.Joslin EP. The Shattuck lecture: the treatment of diabetes mellitus. Boston Med Surg J. 1922;186:833–852. [Google Scholar]
  • 21.Joslin EP. A half-century's experience in diabetes mellitus. Br Med J. 1950;1:1095–1098. doi: 10.1136/bmj.1.4662.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401. [DOI] [PubMed] [Google Scholar]
  • 23.Diabetes Control and Complications Trial Research Group Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:1468–1478. doi: 10.2337/diacare.18.11.1468. [DOI] [PubMed] [Google Scholar]
  • 24.Diabetes Control and Complications Trial Economic Evaluation Writing Team Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA. 1995;276:1409–1415. [PubMed] [Google Scholar]
  • 25.UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type II diabetes (UKPDS 33) Lancet. 1998;352:837–853. [PubMed] [Google Scholar]
  • 26.UK Prospective Diabetes Study Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type II diabetes (UKPDS 34) Lancet. 1998;352:854–865. [PubMed] [Google Scholar]
  • 27.UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type II diabetes (UKPDS 38) Br Med J. 1998;317:703–713. [PMC free article] [PubMed] [Google Scholar]
  • 28.Ohkubo Y, Kishikawah, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective six year study. Diabetes Res Clin Pract. 1995;28:103–117. doi: 10.1016/0168-8227(95)01064-K. [DOI] [PubMed] [Google Scholar]
  • 29.Nathan DM. Some ansers, more controversy, from UKPDS. Lancet. 1998;352:832–833. doi: 10.1016/S0140-6736(98)22937-0. [DOI] [PubMed] [Google Scholar]
  • 30.Walberg P, McKee M, Shkolnikov V, Chenet L, Leon DA. Economic change, crime, and mortality crisis in Russia: regional analysis. Br Med J. 1998;317:312–318. doi: 10.1136/bmj.317.7154.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Lynch JW, Kaplan GA, Pamuk EP, et al. Income inequality and mortality in metropolitan areas of the United States. Am J Public Health. 1998;88:1074–1080. doi: 10.2105/ajph.88.7.1074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Joseph KS, Kramer MS. Review of the evidence on fetal and early childhood antecedents of adult chronic disease. Epidemiol Rev. 1996;18:158–187. doi: 10.1093/oxfordjournals.epirev.a017923. [DOI] [PubMed] [Google Scholar]
  • 33.Rich-Edwards JW, Stamfer MJ, Manson JE, et al. Birthweight and risk of cardiovascular disease in a cohort of women followed-up since 1976. Br Med J. 1997;315:396–400. doi: 10.1136/bmj.315.7105.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Martyn CN, Barker DJP, Osmond C. Mothers' pelvic size, fetal growth and coronary heart disease in men in the UK. Lancet. 1996;348:1264–1268. doi: 10.1016/s0140-6736(96)04257-2. [DOI] [PubMed] [Google Scholar]
  • 35.Lynch JW, Kaplan GA, Salonen JT. Why do poor people behave so poorly? Varaation in adult health behaviors and psycho-social characteristics by stages of the socioeconomic life course. Soc Sci Med. 1997;44:809–820. doi: 10.1016/S0277-9536(96)00191-8. [DOI] [PubMed] [Google Scholar]
  • 36.Lynch JW, Kaplan GA, Cohen RD, et al. Childhood and adult socioeconomic status as predictors of mortality in Finland. Lancet. 1999;343:524–527. doi: 10.1016/s0140-6736(94)91468-0. [DOI] [PubMed] [Google Scholar]
  • 37.Lantz PM, House JS, Lepkowski JM, Wiliams DR, Mero RP, Chen J. Socioeconomic factors, health behaviors and mortality. JAMA. 1998;279:1703–1708. doi: 10.1001/jama.279.21.1703. [DOI] [PubMed] [Google Scholar]
  • 38.Kaplan GA, Lynch JW. Whither studies on the socioeconomic foundations of population health? Am J Public Health. 1997;87:1409–1411. doi: 10.2105/ajph.87.9.1409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Rice D. The cost of instant access to health care. JAMA. 1998;279:1030–1030. doi: 10.1001/jama.279.13.1030. [DOI] [PubMed] [Google Scholar]
  • 40.Budetti PP. Health insurance for children — a model for incremental reform? N Engl J Med. 1998;338:541–542. doi: 10.1056/NEJM199802193380809. [DOI] [PubMed] [Google Scholar]
  • 41.Newacheck PW, Stoddard JJ, Hughes DC, Pearl M. Health insurance and access to primary care for children. N Engl J Med. 1998;338:513–518. doi: 10.1056/NEJM199802193380806. [DOI] [PubMed] [Google Scholar]
  • 42.Seldin TM, Banthin JS, Cohen JW. Medicad's problem children; eligible but not enrolled. Health Aff. 1998;17:192–200. doi: 10.1377/hlthaff.17.3.192. [DOI] [PubMed] [Google Scholar]
  • 43.Reinhardt U. Wanted: a clearly articulated social ethic for American health care. JAMA. 1997;278:1446–1447. doi: 10.1001/jama.278.17.1446. [DOI] [PubMed] [Google Scholar]
  • 44.Moore RD, Stanton D, Goplan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1999;330:763–768. doi: 10.1056/NEJM199403173301107. [DOI] [PubMed] [Google Scholar]
  • 45.Johnson PA, Lee TH, Cook EF, Rounan GW, Goldman L. Effect of race on the presentation and management of patients with acute chest pain. Ann Int Med. 1993;118:593–601. doi: 10.7326/0003-4819-118-8-199304150-00004. [DOI] [PubMed] [Google Scholar]
  • 46.Powe NR, Griffiths RL, deLissovoy G, et al. Access to recombinant erythropoietin by Medicare-eligible renal dialysis patients. JAMA. 1992;277:535–542. [PubMed] [Google Scholar]
  • 47.Diehr P, Yergan J, Chu J, et al. Treatment modality and quality differences for black and white breast cancer patients treated in community hospitals. Med Care. 1998;27:942–958. doi: 10.1097/00005650-198910000-00005. [DOI] [PubMed] [Google Scholar]
  • 48.Peterson ED, Shaw LK, DeLong ER, Pryor DB, Califf RM, Mark DB. Racial variation in the use of coronary-revascularization procedures—are the differences real? Do they matter? N Engl J Med. 1997;336:480–506. doi: 10.1056/NEJM199702133360706. [DOI] [PubMed] [Google Scholar]
  • 49.Todd KH, Samaroo N, Hoffman JR. Ethnicity as a risk factor for inadequate emergency department analgesia. JAMA. 1993;269:1537–1539. doi: 10.1001/jama.269.12.1537. [DOI] [PubMed] [Google Scholar]
  • 50.Eisenberg L. Managed care and the patient-doctor relationship. Paper presented at: American Psychiatric Association Annual Meeting, Toronto, June 1, 1998.
  • 51.Cunningham PJ, Kemper P. Ability to obtain medical care for the uninsured: how much does it vary across communities? JAMA. 1998;280:921–927. doi: 10.1001/jama.280.10.921. [DOI] [PubMed] [Google Scholar]
  • 52.Kassirer J. Managed care and the morality of the marketplace. N Engl J Med. 1995;333:50–52. doi: 10.1056/NEJM199507063330110. [DOI] [PubMed] [Google Scholar]
  • 53.Virchow R. In: Collected Essays on Public Health and Epidemiology. Rather LJ, editor. Canton, Mass: Science History Publications; 1849/1985. pp. 4–4. [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES